Intermittent fasting appears to help stop platelet activation and clot formation, which could help decrease the risk of ...

Since the advent of drug-eluting stents, there has been a debate in the intervention community over how long dual ...

Singh, A. , Sinha, R. , Saran, M. , Kazmi, D. , Gupta, H. and Seth, G. (2025) Efficacy and Safety of Dual Antiplatelet Therapy in High-Risk, Post-Percutaneous Coronary Intervention Patients beyond One ...

Intermittent fasting may significantly reduce the risk of heart attacks and strokes, a new study has revealed. Research ...

TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...

The essential thrombocythemia market is expected to grow steadily due to increasing disease prevalence, advancements in targeted therapies, and risin ...

SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, ...

This was largely due to the US patent expiration of high blood pressure drug, Avapro / Avalide (irbesartan), in March 2012, followed by blood clot treatment Plavix (clopidogrel) in May 2012.

Findings from the nationwide survey suggest interest in PGx while highlighting areas for UK policymakers to pay attention to, ...

The problem can be deadly. The drug clopidogrel, for instance, is routinely given to prevent blood clots in patients after a heart attack. But about a quarter of the population has a gene variant ...